Oligonucleotide Therapy Market Size, Share, Growth, Trends, and Industry Analysis: By Type, By Application, By End User and Region
Oligonucleotide Therapy Market size was valued at US$ 5,183.6 million in 2023 and is expected to grow at an 18.2% CAGR from 2024 to 2030. Oligonucleotides are short-chain DNA or RNA which are generally made using automated synthesizers and the purification process is done by anion exchange chromatography and followed by the techniques of freezing and desalting. Moreover, the oligonucleotides can hold back the expression of specific genes which results in the development of brand-new oligonucleotides targeting certain genes and treating chronic diseases.
The increasing prevalence of infectious diseases such as chickenpox, diphtheria, and the common cold is expected to drive the growth of the oligonucleotides market over the forecast period. In addition, the development of more stable and prolonged half-life molecules due to the advancement of technologies and the upgradation of chemically synthesized oligonucleotides which is anticipated to boost the growth of the oligonucleotides market at a significant rate over the forecast period. Furthermore, an increasing number of mergers, acquisitions, and product launches among the manufacturers and market players to provide medical care to patients are expected to result in the expansion of the oligonucleotide therapy market over the forecast period. For instance, in February 2022, researchers at the University of Illinois Urbana developed a new miRNA point-of-care test for the detection of cancer. The test uses nanoparticles to capture tumor-specific microRNAs (miRNAs) in human serum.
However, the incapability to detect minor antibodies along with the strict regulations are expected to hold back the growth of the oligonucleotide therapy market over the forecast period. Moreover, an increasing number of innovative and technologically advanced product launches are anticipated to provide opportunities in the growth of the oligonucleotides market over the forecast period. Geographically, North America region held the major market share in 2022 and is expected to dominate the global oligonucleotide therapy market in the forecasted years.
Study Period
2024– 2030Base Year
2023CAGR
18.2%Largest Market
North AmericaFastest Growing Market
Asia pacific
The oligonucleotide therapy market is expected to grow over the forecasted period due to the increasing prevalence of genetic disorders and rare diseases. Oligonucleotide therapy has shown a promising result in the treatment of genetic disorders such as Duchenne muscular dystrophy, Huntington’s disease, and cyst fibrosis. In addition, several oligonucleotide therapies have been approved for the treatment of spinal muscular atrophy, hereditary transthyretin-medicated amyloidosis by the USFDA which is expected to drive the growth of oligonucleotide therapy market over the forecast years. Furthermore, development of new stable and extended half-life molecules is expected to boost the market growth over the forecast period.
The oligonucleotide therapy market is segmented based on regions into North America, Asia-pacific, Europe, Latin America, and the Middle East and Africa. The North America oligonucleotide therapy market is likely to hold a significant revenue share, and in the forecasted years, it is predicted to increase rapidly due to the growing prevalence of chronic diseases in this region. In addition, increasing research and development expenditures by the market players is expected to boost the market growth in this region. Asia Pacific region is expected to have a significant growth over the forecast period owing to the surging demand for advanced technologies in oligonucleotide therapeutics in this region.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024– 2030 |
|
Market Size in 2023 |
US$ 5,183.6 million |
|
Market CAGR |
18.2% |
|
By Type |
|
|
By Application |
|
|
By End User |
|
Download Free Sample Report
The global oligonucleotide therapy market was valued at US$ 5,183.6 million in 2023 and is expected to grow at an 18.2% CAGR from 2024 to 2030.
The Oligonucleotide Therapy market is segmented based on type, application, end user, and geography.
The leading players in the global Oligonucleotide Therapy market are BPCI Biotech Holding, SomaGenics Inc., Hepion Pharmaceuticals, Alnylam Pharmaceuticals, Regulus Therapeutics Inc, Ionis Pharmaceuticals, Gilead Sciences Inc, Santaris, InteRNA Technologies B.V., Mirage, Biogen, Merck KGaA, Pfizer Inc.
Historic years considered for the market study are 2019 through 2023, 2023 is considered as the base year for market estimation and Seven years forecast presented from 2024 – 2030.
| 1. Executive Summary |
| 2. Global Oligonucleotide Therapy Market Introduction |
| 2.1.Global Oligonucleotide Therapy Market - Taxonomy |
| 2.2.Global Oligonucleotide Therapy Market - Definitions |
| 2.2.1.Type |
| 2.2.2. Application |
| 2.2.3.End Users |
| 2.2.4.Region |
| 3. Global Oligonucleotide Therapy Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Oligonucleotide Therapy Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Oligonucleotide Therapy Market By Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Antisense |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Ribozymes |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Aptamers |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. miRNA |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. CpG/Immunostimulatory |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. RNAi |
| 5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 6. Global Oligonucleotide Therapy Market By Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Infectious Diseases |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Oncology |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Neurodegenerative Disorders |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Cardiovascular Diseases |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Kidney Diseases |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Others |
| 6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 7. Global Oligonucleotide Therapy Market By End Users, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospitals |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Research Institutes |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Others |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8. Global Oligonucleotide Therapy Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9. North America Oligonucleotide Therapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Antisense |
| 9.1.2.Ribozymes |
| 9.1.3.Aptamers |
| 9.1.4.miRNA |
| 9.1.5.CpG/Immunostimulatory |
| 9.1.6.RNAi |
| 9.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Infectious Diseases |
| 9.2.2.Oncology |
| 9.2.3.Neurodegenerative Disorders |
| 9.2.4.Cardiovascular Diseases |
| 9.2.5.Kidney Diseases |
| 9.2.6.Others |
| 9.3. End Users Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospitals |
| 9.3.2.Research Institutes |
| 9.3.3.Others |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10. Europe Oligonucleotide Therapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Antisense |
| 10.1.2.Ribozymes |
| 10.1.3.Aptamers |
| 10.1.4.miRNA |
| 10.1.5.CpG/Immunostimulatory |
| 10.1.6.RNAi |
| 10.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Infectious Diseases |
| 10.2.2.Oncology |
| 10.2.3.Neurodegenerative Disorders |
| 10.2.4.Cardiovascular Diseases |
| 10.2.5.Kidney Diseases |
| 10.2.6.Others |
| 10.3. End Users Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospitals |
| 10.3.2.Research Institutes |
| 10.3.3.Others |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 11. Asia Pacific (APAC) Oligonucleotide Therapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Antisense |
| 11.1.2.Ribozymes |
| 11.1.3.Aptamers |
| 11.1.4.miRNA |
| 11.1.5.CpG/Immunostimulatory |
| 11.1.6.RNAi |
| 11.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Infectious Diseases |
| 11.2.2.Oncology |
| 11.2.3.Neurodegenerative Disorders |
| 11.2.4.Cardiovascular Diseases |
| 11.2.5.Kidney Diseases |
| 11.2.6.Others |
| 11.3. End Users Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospitals |
| 11.3.2.Research Institutes |
| 11.3.3.Others |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12. Middle East and Africa (MEA) Oligonucleotide Therapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Antisense |
| 12.1.2.Ribozymes |
| 12.1.3.Aptamers |
| 12.1.4.miRNA |
| 12.1.5.CpG/Immunostimulatory |
| 12.1.6.RNAi |
| 12.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Infectious Diseases |
| 12.2.2.Oncology |
| 12.2.3.Neurodegenerative Disorders |
| 12.2.4.Cardiovascular Diseases |
| 12.2.5.Kidney Diseases |
| 12.2.6.Others |
| 12.3. End Users Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospitals |
| 12.3.2.Research Institutes |
| 12.3.3.Others |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13. Latin America Oligonucleotide Therapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Antisense |
| 13.1.2.Ribozymes |
| 13.1.3.Aptamers |
| 13.1.4.miRNA |
| 13.1.5.CpG/Immunostimulatory |
| 13.1.6.RNAi |
| 13.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Infectious Diseases |
| 13.2.2.Oncology |
| 13.2.3.Neurodegenerative Disorders |
| 13.2.4.Cardiovascular Diseases |
| 13.2.5.Kidney Diseases |
| 13.2.6.Others |
| 13.3. End Users Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospitals |
| 13.3.2.Research Institutes |
| 13.3.3.Others |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.BPCI Biotech Holding |
| 14.2.2.SomaGenics Inc. |
| 14.2.3.Hepion Pharmaceuticals |
| 14.2.4.Alnylam Pharmaceuticals |
| 14.2.5.Regulus Therapeutics Inc. |
| 14.2.6.Ionis Pharmaceuticals |
| 14.2.7.Gilead Sciences Inc. |
| 14.2.8.Santaris |
| 14.2.9.InteRNA Technologies B.V. |
| 14.2.10.Mirage |
| 14.2.11.Biogen |
| 14.2.12.Merck KGaA |
| 14.2.13.Pfizer Inc. |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
